GNLX GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Genelux Corp
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Genelux Corp
Did you know?
Capital expenditures increased by 188% from FY24 to FY25.
Current Price
$2.85
+4.01%Profile
Valuation (TTM)
Market Cap$108.45M
P/E-3.37
EV—
P/B9.39
Shares Out38.05M
P/Sales—
Revenue$0.00
EV/EBITDA—
Genelux Corp (GNLX) Quality Analysis
GNLX Profitability
Profitability trend analysis coming soon
GNLX Growth
Growth trend analysis coming soon
GNLX Financial Health
Financial health indicators coming soon
GNLX Quality & Fundamental Analysis
Genelux Corp (GNLX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Genelux Corp's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Genelux Corp has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. and a return on equity (ROE) of -278.46%. Return on assets (ROA) stands at -168.94%.
The debt-to-equity ratio is 0.15, with a current ratio of 2.43.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Genelux Corp is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.